LLY's stock drops despite Q2 earnings beat, as its oral obesity pill underwhelms with 12.4% weight loss in trial.

Novo Nordisk also released its second quarter results this week, boasting profit of more than $4 billion. Per-share earnings ...

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

Novo Nordisk continues to deliver double-digit revenue and profit growth, driven by both its diabetes and obesity drug ...

Novo Nordisk faces slowing revenue growth, weak Q2 2025 results, and a more conservative outlook. Read why I rate NVO stock a ...